← Back to Clinical Trials
Recruiting NCT05024292

NCT05024292 Oriental Research AlliaNce of Acute Ischemic Stroke Given Endovascular Treatment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05024292
Status Recruiting
Phase
Sponsor Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Condition Ischemic Stroke
Study Type OBSERVATIONAL
Enrollment 160 participants
Start Date 2022-01-01
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 95 Years
Study Type OBSERVATIONAL
Interventions
rapid local ischemic postconditioning (RL-IPostC)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 160 participants in total. It began in 2022-01-01 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To determine the safety and efficacy of in situ ischemic postconditioning immediately after successful reperfusion in AIS patients underwnet EVT.

Eligibility Criteria

Inclusion Criteria: 1. Adult (age ≥ 18 to 95 years) patients with an occlusion of the internal carotid artery or M1 or M2 segment of the middle cerebral artery,; 2. Patients with a score of at least 6 on the National Institutes of Health Stroke Scale (NIHSS) at admission and a score of 0 or 1 on the modified Rankin scale before the onset of stroke; 3. Patients with a score of at least 6 on the Alberta Stroke Program Early CT score (ASPECTS) value; 4. Baseline multimodal-CT imaging, including NCCT, CTA and CTP, performed at the trial-site hospital 5. The modified thrombolysis in cerebral infarction (mTICI) scale 2b to 3 achieved in the infarct-related artery after the last thrombectomy attempt Exclusion Criteria: 1. Stoke of large artery atherosclerotic origin or other determined factors (such as dissection) or tandem occlusion; 2. Patients underwent rescue angioplasty or stenting after thrombectomy

Contact & Investigator

Central Contact

Yueqi Zhu, PhD

✉ zhuyueqi@hotmail.com

📞 +86-21-18930177565

Principal Investigator

Yueqi Zhu, PhD

STUDY CHAIR

Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Frequently Asked Questions

Who can join the NCT05024292 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 95 Years, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05024292 currently recruiting?

Yes, NCT05024292 is actively recruiting participants. Contact the research team at zhuyueqi@hotmail.com for enrollment information.

Where is the NCT05024292 trial being conducted?

This trial is being conducted at Zhangzhou, China, Shanghai, China.

Who is sponsoring the NCT05024292 clinical trial?

NCT05024292 is sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital. The principal investigator is Yueqi Zhu, PhD at Shanghai Jiao Tong University Affiliated Sixth People's Hospital. The trial plans to enroll 160 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology